In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 53 for your search:

Drug:  tamoxifen citrate
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO# 08-1373, NCT00900744

Pharmacology of Adjuvant Hormonotherapy in Breast Cancer

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09 SEIN 09, NCT01127295

Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11 SEIN 09, NCT01553903

Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11SEIN12, NCT01612871

Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial)

Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: ECOG-PACCT-1, PACCT-1, NCT00310180

Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000526522, EORTC-10041, EUDRACT-2005-002625-31, BIG-3-04, EU-20676, NOVARTIS-EORTC-10041, ROCHE-EORTC-10041, SANOFI-AVENTIS-EORTC-10041, NCT00433589

HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.

Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HOBOE, NCT00412022

Phase III Randomized Study of Adjuvant Therapy Comprising Tamoxifen Citrate Followed By Either Anastrozole, Letrozole, or Exemestane Versus Anastrozole, Letrozole, or Exemestane Alone in Postmenopausal Women With Resected Endocrine-Responsive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: GIM-3-FATA, GIM3-FATA, EUDRACT-2006-004018-42, EU-20764, NCT00541086

Phase III Randomized Study of Two Different Regimens of Adjuvant Chemotherapy and Trastuzumab (Herceptin®) in Women With HER2-Positive Stage I-IIIA Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: AOUMODENA-SHORT-HER, EudraCT 2007-004326-25, EUDRACT-2007-004326-25, EU-20825, NCT00629278

10.

Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women

Phase: Phase III
Type: Prevention
Status: Active
Age: 30 to 75
Sponsor: Other
Protocol IDs: GD-10-08, NCT00808522

11.

Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: CDR0000635986, COL-MNEMOSYNE, 2007-12, INCA-RECF0899, EUDRACT-2008-003620-32, MNEMOSYNE, NCT00893061

12.

Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: CDR0000638373, CLCC-LETROTAM, VA 2007/09, INCA-RECF0916, EUDRACT-2007-000900-34, LETROTAM, NCT00949598

13.

Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients

Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 349, NCT00896155

14.

Tamoxifen Citrate in Patients With Breast Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: CDR0000650376, CHUV-CEPO-TM, EU-20973, CHUV-CEPO-Tamoxifen metabolism, NCT00963209

15.

Phase III Randomized Study of Standard Adjuvant Endocrine Therapy With Versus Without Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive, and HER2-Negative Breast Cancer

Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S1007, S1007, NCT01272037

16.

Adjuvant AI Combined With Zoladex

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over (Premenopausal)
Sponsor: Other
Protocol IDs: CBCSG002, NCT01352091

17.

Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia

Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: GAL 01, NCT01357772

18.

Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 70 and over
Sponsor: Other
Protocol IDs: GERICO11/PACS10, 2011-004744-22, UC-0103/1102, NCT01564056

19.

Neo-Adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 50
Sponsor: Other
Protocol IDs: KBCSG012, NCT01622361

20.

Phase II Randomized Study of Adjuvant Endocrine Therapy With Versus Without Everolimus in Patients With High-Risk, Hormone Receptor-Positive, and HER2/neu-Negative Breast Cancer

Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S1207, S1207, NCT01674140

21.

Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IFHCC 09-002, NCT01023477

22.

Re-expression of ER in Triple Negative Breast Cancers

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WCI1696-09, NCT01194908

23.

Phase II Study of CA 125 Doubling Time in Patients With Relapsed Advanced Ovarian Carcinoma, Fallopian Tube Carcinoma, or Primary Peritoneal Carcinoma Receiving Tamoxifen Citrate

Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MTVERNHOSP-CA125, EU-205113, NCRN-1509, MREC-EC2003-62, NCT00305838

24.

Phase II Pilot Study of Radiotherapy With Concurrent and Adjuvant Temozolomide, Tamoxifen Citrate, and Carboplatin in Patients With Malignant Gliomas